A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 ...

Please provide your email address to receive an email when new articles are posted on . Diagnostic yield was comparable between navigational bronchoscopy and CT-guided biopsy. Trial investigator ...

Please provide your email address to receive an email when new articles are posted on . Diagnostic accuracy was comparable between navigational bronchoscopy and CT-guided biopsy. Fewer patients with ...

OAK BROOK, Ill. – A new study of more than 10,000 non-smoking adults found that solid lung nodules were present in a considerable portion of study participants. Non-smokers are traditionally thought ...

Adopting a lung nodule program (LNP) may increase the detection of early lung cancer for patients who are not eligible for lung cancer screening under existing age eligibility criteria, according to a ...

Biodesix, Inc. announced a new study published in CHEST Pulmonary Journal reaffirming the effectiveness of its Nodify CDT® blood-based lung nodule test, which assesses seven autoantibodies linked to ...

A new study of more than 10,000 non-smoking adults found that solid lung nodules were present in a considerable portion of study participants. Non-smokers are traditionally thought to be at low risk ...

Dr. Russell Hardie with the Department of Electrical and Computer Engineering has been awarded an National Institutes of Health (NIH) grant to harness artificial intelligence (AI) to revolutionize the ...

LOUISVILLE, Colo. - Biodesix Inc. (NASDAQ:BDSX) announced the publication of a clinical validation study for its Nodify CDT test in Future Oncology in February 2026. The $160.69 million market cap ...

LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE)-- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical ...